pelota mRNA surveillance and ribosome rescue factorGenealiases: CGI-17 · PRO1770
Q-omics provides the consensus-scored PELO profile across patient tissues and cancer cell-line models. PELO expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PELO is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PELO RNA expression shows 18,818 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, HNSC, and UVM as cancer lineages where PELO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PELO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PELO survival associations across molecular data types. PELO RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PELO RNA expression–survival associations across cancer types. High PELO expression shows unfavorable associations in BRCA, UVM, MESO, KIRP and LIHC, but favorable associations in KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PELO RNA expression.
This table summarizes PELO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PELO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PELO shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, COAD, LIHC and BRCA. The HNSC box plot shows higher PELO RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with PELO in patient tissues and cancer cell lines. In patient samples, PELO shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PELO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
